Drug Treatment for Alcoholics With Bipolar Disorder
Completed
University of Pittsburgh
Phase 2
2000-10-01
The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in
treating individuals with alcohol dependence and comorbid bipolar disorder.
Drug Treatment for Alcoholics With Bipolar Disorder
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2000-10-01
The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in
treating individuals with alcohol dependence and comorbid bipolar disorder.
An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.
Completed
Abbott
N/A
2003-07-01
The purpose of this study is to collect and evaluate information on the use of Depakote
Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches.
Patients who are currently in a cluster cycle will be treated with 2 consecutive days of IV
Depacon followed by oral Depakote ER. Patients will receive a total of 1,000mg of Depacon and
1,000mg of Depakote ER each day. Patients may have a 3rd day of IV Depacon followed by oral
Depakote ER if the primary investigator believes it to be beneficial. The patient is then
sent home on oral Depakote ER. The dose of Depakote ER can range from 500mg to 2,000mg this
dose is to be determined by the primary investigator. The patient will continue the oral
Depakote ER until the end of their cluster cycle or for a maximum of 6 weeks, which ever
comes first.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.